Biotechnology company Spyre Therapeutics, Inc. (SYRE) announced Tuesday the appointment of Sheldon Sloan as Chief Medical Officer. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies, including more than 15 years in various leadership roles at J&J.
Sloan is the former Chief Medical Officer at Abivax S.A. where he led the Phase 3 development of obefazimod in ulcerative colitis.
Prior to Abivax, Sloan led the development of etrasimod at Arena Pharmaceuticals, and Pfizer, after Arena's acquisition, where he was responsible for planning, execution, and global submission of the ulcerative colitis program.
Prior to joining Arena, Sloan held leadership positions at J&J in Medical Affairs, R&D, and Science Policy. In his last position at J&J, he was Global Medical Affairs Lead for IBD, responsible for the global launch in Crohn's disease and ulcerative colitis for Stelara.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.